Skip to main content
Premium Trial:

Request an Annual Quote

Abcam Buys MitoSciences for $6M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein research tools firm Abcam today announced it has completed its $6 million buy of MitoSciences.

Abcam, based in Cambridge, UK, paid $4.2 million in cash and issued $1.8 million of Abcam shares at $397.1 pence per share as part of the deal. The purchase will enhance the range of products available to its customers, Abcam said.

Based in Eugene, Ore., MitoSciences develops mitochondrial antibodies and assays focusing on metabolism and apoptosis. Last year, it won a $590,000 NIH grant to develop companion diagnostic tests for antiviral drugs.

MitoSciences employs 24 people and has a catalog of more than 200 products, Abcam said. In 2010, MitoSciences generated product revenues of $2.1 million and had net assets of $600,000.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.